MAZE THERAPEUTICS INC (MAZE) Stock Fundamental Analysis

NASDAQ:MAZE • US5787841007

45.3 USD
-0.24 (-0.53%)
At close: Feb 24, 2026
45.3 USD
0 (0%)
After Hours: 2/24/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

MAZE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While MAZE has a great health rating, its profitability is only average at the moment. MAZE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • MAZE had negative earnings in the past year.
  • In the past year MAZE has reported a negative cash flow from operations.
MAZE Yearly Net Income VS EBIT VS OCF VS FCFMAZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • MAZE has a better Return On Assets (0.81%) than 80.73% of its industry peers.
  • The Return On Equity of MAZE (0.90%) is better than 80.73% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 11.37%, MAZE belongs to the top of the industry, outperforming 91.15% of the companies in the same industry.
Industry RankSector Rank
ROA 0.81%
ROE 0.9%
ROIC 11.37%
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAZE Yearly ROA, ROE, ROICMAZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin of MAZE (2.03%) is better than 79.69% of its industry peers.
  • The Operating Margin of MAZE (34.38%) is better than 95.31% of its industry peers.
Industry RankSector Rank
OM 34.38%
PM (TTM) 2.03%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAZE Yearly Profit, Operating, Gross MarginsMAZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MAZE is creating some value.
  • MAZE has about the same amout of shares outstanding than it did 1 year ago.
  • There is no outstanding debt for MAZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MAZE Yearly Shares OutstandingMAZE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MAZE Yearly Total Debt VS Total AssetsMAZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 31.24 indicates that MAZE is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 31.24, MAZE belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
  • MAZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 31.24
ROIC/WACC1.23
WACC9.22%
MAZE Yearly LT Debt VS Equity VS FCFMAZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • MAZE has a Current Ratio of 17.70. This indicates that MAZE is financially healthy and has no problem in meeting its short term obligations.
  • MAZE has a Current ratio of 17.70. This is amongst the best in the industry. MAZE outperforms 88.54% of its industry peers.
  • A Quick Ratio of 17.70 indicates that MAZE has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 17.70, MAZE belongs to the best of the industry, outperforming 88.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.7
Quick Ratio 17.7
MAZE Yearly Current Assets VS Current LiabilitesMAZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • MAZE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 103.39%, which is quite impressive.
EPS 1Y (TTM)103.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1086.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • MAZE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.42% yearly.
  • MAZE is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.73% yearly.
EPS Next Y86.65%
EPS Next 2Y36.7%
EPS Next 3Y22.92%
EPS Next 5Y13.42%
Revenue Next Year-100%
Revenue Next 2Y-89.7%
Revenue Next 3Y-70.63%
Revenue Next 5Y-8.73%

3.3 Evolution

MAZE Yearly Revenue VS EstimatesMAZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
MAZE Yearly EPS VS EstimatesMAZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • MAZE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MAZE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAZE Price Earnings VS Forward Price EarningsMAZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MAZE indicates a somewhat cheap valuation: MAZE is cheaper than 79.17% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.91
MAZE Per share dataMAZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

  • MAZE's earnings are expected to grow with 22.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.7%
EPS Next 3Y22.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MAZE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MAZE THERAPEUTICS INC

NASDAQ:MAZE (2/24/2026, 8:00:01 PM)

After market: 45.3 0 (0%)

45.3

-0.24 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)N/A
Inst Owners74.46%
Inst Owner Change10.1%
Ins Owners1.88%
Ins Owner Change-32.52%
Market Cap2.18B
Revenue(TTM)167.50M
Net Income(TTM)3.40M
Analysts86.67
Price Target48.96 (8.08%)
Short Float %6.52%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.25%
Min EPS beat(2)8.68%
Max EPS beat(2)11.81%
EPS beat(4)2
Avg EPS beat(4)-1030.11%
Min EPS beat(4)-4091.29%
Max EPS beat(4)11.81%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.07%
PT rev (3m)23.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.65%
EPS NY rev (1m)0.07%
EPS NY rev (3m)1.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.01
P/FCF N/A
P/OCF N/A
P/B 5.74
P/tB 5.74
EV/EBITDA 28.91
EPS(TTM)-20.9
EYN/A
EPS(NY)-3.2
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS3.48
BVpS7.89
TBVpS7.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.81%
ROE 0.9%
ROCE 14.4%
ROIC 11.37%
ROICexc 284.14%
ROICexgc 284.14%
OM 34.38%
PM (TTM) 2.03%
GM N/A
FCFM N/A
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 52.32%
Cap/Sales 0.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.7
Quick Ratio 17.7
Altman-Z 31.24
F-Score6
WACC9.22%
ROIC/WACC1.23
Cap/Depr(3y)32.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1086.28%
EPS Next Y86.65%
EPS Next 2Y36.7%
EPS Next 3Y22.92%
EPS Next 5Y13.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-89.7%
Revenue Next 3Y-70.63%
Revenue Next 5Y-8.73%
EBIT growth 1Y158.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-660.53%
EBIT Next 3Y-105.62%
EBIT Next 5YN/A
FCF growth 1Y185.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y187.48%
OCF growth 3YN/A
OCF growth 5YN/A

MAZE THERAPEUTICS INC / MAZE FAQ

What is the ChartMill fundamental rating of MAZE THERAPEUTICS INC (MAZE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MAZE.


What is the valuation status of MAZE THERAPEUTICS INC (MAZE) stock?

ChartMill assigns a valuation rating of 1 / 10 to MAZE THERAPEUTICS INC (MAZE). This can be considered as Overvalued.


Can you provide the profitability details for MAZE THERAPEUTICS INC?

MAZE THERAPEUTICS INC (MAZE) has a profitability rating of 4 / 10.